Julie Boerner

 

 

 

 

 

 

Julie Boerner, Ph.D.
Assistant Professor
816 HWCRC
4100 John R.
Detroit, MI 48201
boernerj@karmanos.org

Research Interests:

  • Role of c-Met in EGFR tyrosine kinase inhibitor resistance in breast cancer.
  • Lipid raft localization of EGFR family members as a mechanism of resistance to EGFR inhibitors in breast cancer.
  • Role of tyrosine 845 phosphorylation on EGFR on migration and transformation of breast cancer cells.
  • Src regulation of Ras activity in pancreatic cancer.

Research Description:

My laboratory is interesting in studying the mechanisms of EGFR kinase-independent signaling in breast cancers. Specifically, we are interested in identifying crosstalk between EGFR and other tyrosine kinases that mediate EGFR kinase-independent signaling and determining the role of these identified kinases in EGFR tyrosine kinase inhibitor resistance in breast cancer.

Selected Publications:

Bao B, Mitrea C, Wijesinghe P, Marchetti L, Girsch E, Farr RL, Boerner JL, Mohammad R, Dyson G, Terlecky SR, Bollig-Fischer A. Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity.  Sci Rep. 2017;7:44125.

Linklater ES, Tovar EA, Essenburg CJ, Turner L, Madaj Z, Winn ME, Melnik MK, Korkaya H, Maroun CR, Christensen JG, Steensma MR, Boerner JL, Graveel CR. Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers.  Oncotarget. 2016 Oct 25;7(43):69903-15.

Zoratti GL, Tanabe LM, Hyland TE, Duhaime MJ, Colombo É, Leduc R, Marsault E, Johnson MD, Lin CY, Boerner J, Lang JE, List K. Matriptase regulates c-Met mediated proliferation and invasion in inflammatory breast cancer. Oncotarget. 2016;7:58162-73.

Joiakim A, Mathieu PA, Shelp C, Boerner J, Reiners JJ Jr. Epidermal Growth Factor Receptor Kinase Inhibitors Synergize with TCDD to Induce CYP1A1/1A2 in Human Breast Epithelial MCF10A Cells. Drug Metab Dispos. 2016;44:665-71.

LoRusso PM, Li J, Burger A, Heilbrun LK, Sausville EA, Boerner SA, Smith D, Pilat MJ, Zhang J, Tolaney SM, Cleary JM, Chen AP, Rubinstein L, Boerner JL, Bowditch A, Cai D, Bell T, Wolanski A, Marrero AM, Zhang Y, Ji J, Ferry-Galow K, Kinders RJ, Parchment RE, Shapiro GI. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors. Clin Cancer Res. 2016;22:3227-37.

Education and Training
BS in Molecular Biology (1993): University of Wisconsin
MS in Endocrinology Reproductive-Physiology (1996): University of Wisconsin
PhD Tumor Biology (2000): Mayo Clinic
University of Virginia, post-doctoral fellowship with Dr. Sarah Parsons

Cancer Biology Courses Taught:
CB7300 F31 Grant Writing Course
CB7460 Mechanism of Neoplasia: Alterations to Cellular Signaling
CB7700 Recent Developments in Cancer Biology
CB7990 Research Technologies in Cancer Research